Clinical Trial

Kamlanoflast In Amyotrophic Lateral Sclerosis

Name: Kamlanoflast In Amyotrophic Lateral Sclerosis — clinical trial record (NCT07396818)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.

Trial Details

NCT Number	NCT07396818
Lead Sponsor	Inflammasome Therapeutics
Conditions	ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Motor Neuron Disease (MND)
Enrollment	40 participants
Start Date	2026-02
Primary Completion	2027-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-09